Advanced Certificate in Drug Targeting for Hematologic Malignancies

• Drug Discovery and Design: Introduction to drug discovery process, target identification, lead optimization, and computational drug design.
• Pharmacology of Hematologic Malignancies: Overview of hematologic malignancies, pathophysiology, molecular targets, and current treatments.
• Molecular Mechanisms of Drug Resistance: Analysis of drug resistance mechanisms, genetic and epigenetic factors, and strategies to overcome resistance.
• Monoclonal Antibodies and Immunoconjugates: Principles of monoclonal antibody design, antibody-drug conjugates (ADCs), and their applications in hematologic malignancies.
• Small Molecule Inhibitors: Overview of small molecule inhibitors, protein kinase inhibitors, and their role in treating hematologic malignancies.
• Nucleic Acid-Based Therapeutics: Introduction to nucleic acid-based therapeutics, antisense oligonucleotides, RNA interference, and gene therapy.
• Immunotherapy in Hematologic Malignancies: Overview of immunotherapeutic approaches, immune checkpoint inhibitors, chimeric antigen receptor T-cell therapy (CAR-T), and dendritic cell therapy.
• Clinical Trials and Translational Research: Design and implementation of clinical trials, translational research, and regulatory considerations in drug targeting for hematologic malignancies.
• Personalized Medicine and Precision Oncology: Principles of personalized medicine, pharmacogenomics, biomarker discovery, and their role in drug targeting for hematologic malignancies.